Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients

Schizophrenia Research

Volumn 42, Issue 1, 2000, Pages 7-17

  Yao, Jeffrey K ^a,b   Leonard, Sherry ^c   Reddy, Ravinder D ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Arachidonic acid; Caudate; Phospholipids; Polyunsaturated fatty acids; Postmortem changes

Indexed keywords

ARACHIDONIC ACID; MEMBRANE PHOSPHOLIPID; POLYUNSATURATED FATTY ACID;

ADULT; AGED; ARTICLE; AUTOPSY; BRAIN TISSUE; CADAVER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MALE; MENTAL DISEASE; PRIORITY JOURNAL; SCHIZOPHRENIA;

ARACHIDONIC ACID; BRAIN; CELL MEMBRANE; CHROMATOGRAPHY, GAS; FATTY ACIDS; FATTY ACIDS, UNSATURATED; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLETHANOLAMINES; PHOSPHOLIPIDS; POSTMORTEM CHANGES; SCHIZOPHRENIA; SMOKING; TIME FACTORS;

EID: 0033998227     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(99)00095-X     Document Type: Article

References (62)

1. Breton L., Serkiz B., Volland J.P., Lepagnol J. A new rapid method for phospholipid separation by high-performance liquid chromatography with light-scattering detection. J. Chromatogr. 497:1989;243-249.
2. Christie W.W. Rapid separation and quantification of lipid classes by high-performance liquid chromatography and mass (light-scattering) detection. J. Lipid Res. 26:1985;507-512.
3. Das I., Essali M.A., Debelleroche J., Hirch S.R. Inositol phoslipid turnover in platelet of schizophrenic patients. Prostagland. Leukotr. Essent. Fatty Acids. 46:1992;65-66.
4. 31Phosphorus MRSI in the frontal and parietal lobes in schizophrenia. Biol. Psychiatry. 33:1993;46A. Abstract.
5. Deicken R.F., Merrin E.L., Floyd T.C., Weiner M.W. Correlation between left frontal phospholipids and Wisconsin Card Sort Test performance in schizophrenia. Schizophr. Res. 14:1995;177-181.
6. Demisch L., Heinz K., Gerbaldo H., Kirsten R. Increased concentrations of phosphatidyl-inositol and decreased esterification of arachidonic acid into phospholipids in platelets from patients with schizoaffective disorders or atypic phasic psychoses. Prostagland. Leukotr. Essent. Fatty Acids. 46:1992;47-52.
7. Edwards E., Ashby C.R. Jr., Wang R.Y. The effect of typical and atypical antipsychotic drugs on the stimulation of phosphoinositide hydrolysis produced by the 5-HT3 receptor agonist 2-methyl-serotonin. Brain Res. 545:1991;276-278.
8. Essali M.A., Das I., Belleroche J., Hirsch S.R. The platelet phosphoinositide system in schizophrenia: The effects of neuroleptic treatment. Biol. Psychiatry. 28:1990;475-487.
9. Friedel R.O., Knauer G. Actions of neuroleptics on the acetylcholine-induced phospholipid effect in rat neostriatal homogenates. Psychopharmacology. 20:1981;925-930.
10. 31P magnetic resonance spectroscopy of schizophrenic patients with neuroleptic-resistant positive and negative symptoms. Biol. Psychiatry. 31(S):1992;204A-205A. Abstract.
11. Fukuzako H., Fukuzako T., Takeuchi K., Ohbo Y., Ueyama K., Takigawa M., Fujimoto T. Phosophorus magnetic resonance spectroscopy in schizophrenia: Correlation between membrane phospholipid metabolism in temporal lobe and positive symptoms. Prog. Neuropsychopharma. Biol. Psychiary. 20:1996;629-640.
12. Gattaz W.F., Köllisch M., Thuren T., Virtanen J.A., Kinnunen P.K.J. Increased plasma phospholipase-A2 activity in schizophrenic patients: Reduction after neuroleptic therapy. Biol. Psychiatry. 22:1987;421-426.
13. Gattaz W.F. Phospholipase A2 in schizophrenia. Biol. Psychiatry. 31:1992;209-216.
14. Glen A.I.M., Glen E.M.T., Horrobin D.F., et al. A red cell membrane abnormality in a sub-group of schizophrenic patients: Evidence for two diseases. Schizophr. Res. 12:1994;53-61.
15. Glen A.I.M., Cooper S.J., Rybakowsky J., Vaddadi K., Brayshaw N., Horrobin D.F. Membrane fatty acids, niacin flushing and clinical parameters. Prostaglandins Leukotr. Essent. Fatty Acids. 55:1996;9-15.
16. Horrobin D.F. Schizophrenia: A biochemical disorder. Biomedicine. 32:1980;54-55.
17. Horrobin D.F., Manku M.S., Hillman H., Iain A., Glen M. Fatty acid levels in the brains of schizophrenics and normal controls. Biol. Psychiatry. 30:1991;795-805.
18. Horrobin D.F., Glen A.I.M., Hudson C.J. Possible relevance of phospholipid abnormalities and genetic interactions in psychiatric disorders: The relationship between dyslexia and schizophrenia. Med. Hypotheses. 45:1995;605-613.
19. Horrobin D.F. Schizophrenia as a membrane lipid disorder which is expressed throughout the body. Prostagland. Leukotr. Essent. Fatty Acids. 55:1996;3-7.
20. Horrobin D.F., Manku M.S., Morse-Fisher N., Vaddadi K.S., Courtney P., Glen A.I.M., et al. Essential fatty acids in plasma phospholipids in schizophrenics. Biol. Psychiatry. 25:1989;562-568.
21. Hudson C.J., Lin A., Cogan S., Cashman F., Warsh J.J. The niacin challenge test: clinical manifestation of altered transmembrane signal transduction in schizophrenia? Biol. Psychiatry. 41:1997;507-513.
22. Hughes J.R., Hatsukami D.K., Mitchell J.E., Dahlgren L.A. Prevalence of smoking among psychiatric outpatients. Am. J. Psychiatry. 143:1986;993-997.
23. Jope R.S., Song L., Powers R. Agonist-induced, GTP-dependent phosphoinositide hydrolysis in postmortem human brain membranes. J. Neurochem. 62:1994;180-186.
24. Jope R.S., Song L., Li P.P., Young L.T., Kish S.J., Pacheco M.A., et al. The phosphoinositide signal transduction system is impaired in bipolar affective disorder brain. J. Neurochem. 66:1996;2402-2409.
25. Jope R.S., Song L., Grimes C.A., Pacheco M.A., Dilley G.E., Li X., et al. Selective increases in phosphoinositide signaling activity and G protein levels in postmortem brain from subjects with schizophrenia or alcohol dependence. J. Neurochem. 70:1998;763-771.
26. Kaiya H., Horrobin D.F., Manku M.S., Morse-Fisher N. Essential and other fatty acids in plasma in schizophrenics and normal individuals from Japan. Biol. Psychiatry. 30:1991;357-362.
27. Keshaven M.S., Mallinger A.G., Pettegrew J.W., Dippold C. Erythrocyte membrane phospholipids in psychotic patients. Psychiatr. Res. 49:1993;89-95.
28. Keshaven M.S., Pettegrew J.W., Ward R. Are membrane phospholipid changes in schizophrenia familial? Biol. Psychiatry. 33:1993;45A. Abstract.
29. Leonard S., Logel J., Luthman D., Casanova M., Kirch D., Freedman R. Biological stability of MRNA isolated from human postmortem brain collections. Biol. Psychiatry. 33:1993;456-466.
30. Letter W.S. A rapid method for phospholipid class separation by HPLC using an evaporative light-scattering detector. J. Liquid Chromatogr. 15:1992;253-266.
31. Li R., Wang L.L., Kirch D.G., Wyatt R.J., Chuang D.-M. Effects of chronic nicotine and haloperidol administration on muscarinic receptor-mediated phosphoinositide turnover in rat brain slices. Psychopharmacology. 109:1992;248-250.
32. Li R., Chuang D-M., Wyatt R.J., Kirch D.G. Effect of chronic haloperidol treatment on dopamine-induced inositol phosphate formation in rat brain slices. Neurochem. Res. 19:1994;673-678.
33. Mahadik S.P., Mukherjee S., Correnti E., Kelkar H.S., Wakade C.G., Costa R.M., et al. Distribution of plasma membrane phospholipids and cholesterol in skin fibroblasts from drug-naive patients at the onset of psychosis. Schizophr. Res. 13:1994;239-247.
34. Nilsson A., Horrobin D.F., Rosengren A., Waller L., Adlerberth A., Wilhelmsen L. Essential fatty acids and abnormal involuntary movements in the general male population: a study of men born in 1933. Prostagland. Leukotr. Essent. Fatty Acids. 55:1996;83-87.
35. Noponen M., Sanfilipo M., Samanich K., Ryer H., Ko G., Angrist B., et al. Elevated PLA2 activity in schizophrenics and other psychiatric patients. Biol. Psychiatry. 34:1993;641-649.
36. Olincy A., Young D.A., Freedman R. Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. Biol. Psychiatry. 42:1997;1-5.
37. O'Neill C., Fowler C.J., Wiehager B., Alafuzuff I., Winblad B. Assay of a phosphatidylinositol bisphosphate phospholipase C activity in postmortem human brain. Brain Res. 543:1991;307-314.
38. Pacheco M.A., Jope R.S. Phosphoinositide signaling in human brain. Prog. Neurobiol. 50:1996;255-273.
39. Peet M., Laughame J.D.E., Rangarajan N., Horrobin D.F., Reynolds G. Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients. J. Psychiatr. Res. 29:1995;227-232.
40. Peet M., Laugharne J.D.E., Mellor J., Ramchand C.N. Essential fatty acid deficiency in eyrthrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation. Prostagland. Leukotr. Essent. Fatty Acids. 55:1996;71-75.
41. Pettegrew J.W., Keshavan M.S., Panchalingam K., Strychor S., Kaplan D.B., Tretta M.G., et al. Alterations in brain high energy phosphate and membrane phospholipid metabolism in first episode drug naïve schizophrenics. Arch. Gen. Psychiatry. 48:1991;563-568.
42. 31P nuclear magnetic resonance spectroscopy: Neurodevelopment and schizophrenia. Schizophr. Bull. 19:1993;335-353.
43. Reddy, R.D., Yao, J.K., in press. Schizophrenia: Role of oxidative stress and essential fatty acids. In: Temple and Basn (Eds.), Antioxidants and Disease.
44. Rotrosen J., Wolkin A. Phospholipid and prostaglandin hypotheses of schizophrenia. Meltzer N.Y. Psychopharmacology. The Third Generation on Progress. 1987;759-764 Raven Press, New York.
45. Shioiri T., Kato T., Inubushi T., Murashita J., Takahashi S. Correlations of phosphomonoesters measured by phosphorus-31 magnetic resonance spectroscopy in the frontal lobes and negative symptoms in schizophrenia. Psychiatr. Res. 55:1994;223-235.
46. 31P MR spectroscopy study. Schizophr. Res. 13:1994;209-215.
47. Svennerholm L., Bostrom K., Helander C.G., Jungbjer B. Membrane lipids in the aging human brain. J. Neurochem. 56:1991;2051-2059.
48. Tacconi M.T., Calzi F., Salmona M. Brain lipids and diet. Hillbrand M., Spitz T.S. Lipids, Health and Behavior. 1997;197-226 American Psychological Association, Washington, DC.
49. Vaddadi K.S., Courtney P., Gillard C.J., Manku M.S., Horrobin D.F. A double blind trial of essential fatty acid supplementation in patients with tardive dyskinesia. Psychiatr. Res. 27:1989;313-323.
50. Vaddadi K.S. Dyskinesias and their treatment with essential fatty acids: a review. Prostagland. Leukotr. Essent. Fatty Acids. 55:1996;89-94.
51. Vijayaraghavan S., Huang B., Blumenthal E.M., Berg D.K. Arachidonic acid as a possible negative feedback inhibitor of nicotinic acetylcholine receptors on neurons. J. Neurosci. 15:1995;3679-3687.
52. Wallace M.A., Claro E. Transmembrane signalling through phospholipase C in human cortical membranes. Neurochem. Res. 18:1993;139-145.
53. Williamson P., Drost D., Stanley J., Carr T., Morrison S., Merskey H. Localized phosphorus 31 magnetic resonance spectroscopy in chronic schizophrenic patients and normal controls. Arch. Gen. Psychiatr. 48:1991;578. Letter.
54. Yao J.K., Yasei P., van Karnmen D.P. Increased turnover of platelet phosphatidylinositol in schizophrenia. Prostagland. Leukotr. Essent. Fatty Acids. 46:1992;39-46.
55. Yao J.K., van Kammen D.P. Red blood cell membrane dynamics in schizophrenia. I. Membrane fluidity. Schizophr. Res. 11:1994;209-216.
56. Yao J.K., van Kammen D.P., Gurklis J. Red blood cell membrane dynamics in schizophrenia. III. Correlation of fatty acid abnormalities with clinical measures. Schizophr. Res. 13:1994;227-232.
57. Yao J.K., van Kammen D.P., Gurklis J., Peters J.L. Platelet aggregation and secretion in schizophrenia. Psychiatr. Res. 54:1994;13-24.
58. Yao J.K., van Kammen D.P., Welker J.A. Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition. Schizophr. Res. 13:1994;217-226.
59. 3H]arachidonic acid into platelet phospholipids of patients with schizophrenia. Prostagland. Leukotr. Essent. Fatty Acids. 55:1996;21-26.
60. Yao J.K., van Kammen D.P., Gurklis J. Abnormal incorporation of arachidonic acid into platelets of drug-free patients with schizophrenia. Psychiatr. Res. 60:1996;11-21.
61. Yao J.K., van Kammen D.P., Moss H.B., Sokulski D.E. A decreased serotonergic responsivity in platelets of unmedicated patients with schizophrenia. Psychiatr. Res. 63:1996;123-132.
62. Zubenko G.S., Cohen B.M. A cell membrane correlate of tardive dyskinesia in patients treated with phenothiazines. Psychopharmacology. 88:1986;230-236.